These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 7451712)

  • 1. [Immunization against malignant tumors using a suspension of sonicated tumors cells].
    Erokhin VN; Braginskaia FI
    Izv Akad Nauk SSSR Biol; 1980; (6):932-4. PubMed ID: 7451712
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth.
    BenAmmar-Ceccoli S; Humblot S; Crouzier R; Acres B; Kieny MP; Herlyn D; Pasquali JL; Martin T
    Cancer Gene Ther; 2001 Oct; 8(10):815-26. PubMed ID: 11687905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect.
    Pokorná D; Macková J; Dusková M; Rittich S; Ludvíková V; Smahel M
    J Gene Med; 2005 Jun; 7(6):696-707. PubMed ID: 15712328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprevention of cancer: time to reconsider timing of vaccination against cancer.
    Spisek R
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1689-91. PubMed ID: 17181481
    [No Abstract]   [Full Text] [Related]  

  • 5. Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells.
    Smahel M; Síma P; Ludvíková V; Vonka V
    Virology; 2001 Mar; 281(2):231-8. PubMed ID: 11277695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells.
    Lechanteur C; Moutschen M; Princen F; Lopez M; Franzen E; Gielen J; Bours V; Merville MP
    Cancer Gene Ther; 2000 May; 7(5):676-82. PubMed ID: 10830715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.
    Nair SK; Heiser A; Boczkowski D; Majumdar A; Naoe M; Lebkowski JS; Vieweg J; Gilboa E
    Nat Med; 2000 Sep; 6(9):1011-7. PubMed ID: 10973321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of transplanted rat tumors by immunization with identical tumor cells infected with Friend virus.
    Kobayashi H; Sendo F; Kaji H; Shirai T; Saito H; Takeichi N; Hosokawa M; Kodama T
    J Natl Cancer Inst; 1970 Jan; 44(1):11-9. PubMed ID: 11515021
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic immunization with the free human chorionic gonadotropin beta subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice.
    Geissler M; Wands G; Gesien A; de la Monte S; Bellet D; Wands JR
    Lab Invest; 1997 Jun; 76(6):859-71. PubMed ID: 9194861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination.
    Chambers B; Grufman P; Fredriksson V; Andersson K; Roseboom M; Laban S; Camps M; Wolpert EZ; Wiertz EJ; Offringa R; Ljunggren HG; van Hall T
    Cancer Res; 2007 Sep; 67(18):8450-5. PubMed ID: 17875682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
    Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
    J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
    Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
    Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities.
    Ribas A; Bui LA; Butterfield LH; Vollmer CM; Jilani SM; Dissette VB; Glaspy JA; McBride WH; Economou JS
    Anticancer Res; 1999; 19(2A):1165-70. PubMed ID: 10368670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells.
    Oizumi S; Deyev V; Yamazaki K; Schreiber T; Strbo N; Rosenblatt J; Podack ER
    J Immunother; 2008 May; 31(4):394-401. PubMed ID: 18391756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
    Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
    Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does preventive vaccination with engineered tumor cells work in cancer-prone transgenic mice?
    Morel A; de La Coste A; Fernandez N; Berson A; Kaybanda M; Molina T; Briand P; Haddada H; Guillet JG; Antoine B; Viguier M; Kahn A
    Cancer Gene Ther; 1998; 5(2):92-100. PubMed ID: 9570300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity.
    Chen XY; Zhang W; Zhang W; Wu S; Bi F; Su YJ; Tan XY; Liu JN; Zhang J
    Clin Cancer Res; 2006 Oct; 12(19):5834-40. PubMed ID: 17020991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor resistance formation in animals in early neonatal period.
    Kazmin SD; Todor IN; Chekhun VE
    J Exp Clin Cancer Res; 2007 Mar; 26(1):83-90. PubMed ID: 17550136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
    Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
    J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.